Clinical and ophthalmic evaluation of the effectiveness of comprehensive treatment regimen for central serous chorioretinopathy

The purpose of the study is to evaluate the clinical-ophthalmological effectiveness of the developed complex treatment for central serous chorioretinopathy (CSC) using subthreshold micro-pulse laser (SMILV) exposure with a wavelength of 577 nm combined with platelet autoplasm (TP) injections in the pterygopalatine fossa, which is the region of hemolymphocirculation. Material and Methods. The study was conducted on 60 patients (60 eyes) with CSC. Patients were divided into 2 groups: in the comparison group patients received treatment with SMILV with a wavelength of 577 nm only, while in the main group they received treatment with SMILV and subsequent TP injections. The patients were prescribed 3 injections into the pterygopalatine fossa on the side of the affected eye, which is the region of the hemolymphocirculation, with the 72-hour-long interval between injections. SMILV was carried out on a Supra 577 nm laser (Quantel Medical, France) over the entire area of macular edema. Results. The results of the application of the developed and patented treatment for patients with CSC with the use of SMILV 577 nm combined with enriched TP injections are presented in the study. Comparative analysis of clinical and ophthalmic effectiveness of the proposed method of treatment was compared with monotherapy with SMILV 577 nm 1, 3, 6 and 12 months after treatment. Conclusion. This method has been developed and introduced into clinical practice for combined treatment of patients with CSC. The study demonstrates great clinical and ophthalmic effectiveness of the combined treatment.